 Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC Nasdaq on July 9, 2020 indicating that Lipocine has regained compliance with Nasdaqs minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550a2 Min Bid Price Listing Rule. 